Type 2 Diabetes

Research presented at the American Heart Association provided new insight into  two large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.

Diet may play a major role in magnesium and its association to type 2 diabetes.

New insulin formulation emerges as safe alternative to long-acting insulins and inconsistent glycemic levels, but could have higher risk of cardiovascular events.

New study finds that adults with type 2 diabetes and atherosclerotic cardiovascular disease have increased risk of mortality with a prior nonfatal cardiovascular (CV) event.

Once-weekly exenatide formulation can provide as much benefit as the traditional twice-daily dosing.

High linoleic acid level could reduce type 2 risk by 43 percent, new study found.

Patients with type 2 diabetes not responding to basal insulin therapy alone may see glycemic improvement with a GLP-1 receptor agonist.

New study finds incidence of thyroid disorders in people with diabetes no higher than than those without.

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.